株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

掻痒:パイプライン分析

Pruritus - Pipeline Review, H1 2019

発行 Global Markets Direct 商品コード 213132
出版日 ページ情報 英文 158 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
掻痒:パイプライン分析 Pruritus - Pipeline Review, H1 2019
出版日: 2019年04月29日 ページ情報: 英文 158 Pages
概要

掻痒とは、かゆみによる不快感を意味し、皮膚の発赤、腫れ、斑点、水膨れ、乾燥、ひび割れ、革状化、鱗状化などの症状があります。温度やアレルギー、喘息、花粉症、蕁麻疹、皮膚炎などのリスクファクターがあり、コルチコステロイド剤、抗ヒスタミン薬、抗鬱剤の投与などの治療法があります。

当レポートでは、世界における掻痒治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

掻痒の概要

治療薬の開発

  • 掻痒向けパイプライン製品:概要
  • 掻痒向けパイプライン製品:比較分析

掻痒:開発中の治療薬:企業別

掻痒:開発中の治療薬:大学・研究機関別

掻痒:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

掻痒:開発中の製品:企業別

掻痒:開発中の製品:大学・研究機関別

掻痒:治療薬開発に従事している企業

  • AlbireoPharma
  • Amorepacific Corporation
  • Cara Therapeutics, Inc.
  • 中外製薬
  • Creabilis SA
  • ELORAC, Inc.
  • Faes Farma, SA
  • GlaxoSmithKline Plc
  • Hydra Biosciences, Inc.
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • NeRRe Therapeutics Ltd
  • 日本新薬
  • Patara Pharma, Inc.
  • Phosphagenics Limited
  • RDD Pharma Ltd.
  • 三和化学研究所
  • 塩野義製薬
  • 大日本住友製薬
  • Tioga Pharmaceuticals, Inc.
  • Trevi Therapeutics, Inc.
  • Vanda Pharmaceuticals Inc.

掻痒:治療薬の評価

  • 単剤治療薬
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • >A-4250
    • 製品概要
    • 作用機序
    • R&Dの進捗
  • アプレピタント(制吐薬)
  • asimadoline
  • ASN-008
  • bilastine
  • C-745
  • CR-845
  • クロモグリク酸ナトリウム
  • CT-327
  • CT-340
  • desloratadine
  • GSK-2330672
  • 塩酸リドカイン
  • 塩酸ナルブフィン ER
  • 塩酸ナロキソン
  • nemolizumab
  • NS-141
  • orvepitant maleate
  • PAC-14028
  • 疼痛・掻痒向けTRPV1標的ペプチド
  • RDD-1609
  • serlopitant
  • SK-1405
  • 掻痒向けCB2作動薬
  • 掻痒向けP物質阻害薬
  • 掻痒・乾癬向けTRPV3拮抗薬
  • 疼痛・掻痒向けNaV1.7チャネル遮断薬
  • 掻痒向けMas関連Gタンパク質共役受容体阻害剤
  • tradipitant

最新のパイプライン動向

休止中のプロジェクト

中止された製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Pruritus, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Companies, H1 2019 (Contd..2), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Pruritus - Pipeline by Albireo Pharma Inc, H1 2019
  • Pruritus - Pipeline by Amgen Inc, H1 2019
  • Pruritus - Pipeline by AOBiome LLC, H1 2019
  • Pruritus - Pipeline by Asana BioSciences LLC, H1 2019
  • Pruritus - Pipeline by Cara Therapeutics Inc, H1 2019
  • Pruritus - Pipeline by Celgene Corp, H1 2019
  • Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2019
  • Pruritus - Pipeline by ELORAC Inc, H1 2019
  • Pruritus - Pipeline by GlaxoSmithKline Plc, H1 2019
  • Pruritus - Pipeline by Hanlim Pharm Co Ltd, H1 2019
  • Pruritus - Pipeline by Hydra Biosciences Inc, H1 2019
  • Pruritus - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2019
  • Pruritus - Pipeline by Menlo Therapeutics Inc, H1 2019
  • Pruritus - Pipeline by NeuroCycle Therapeutics GmbH, H1 2019
  • Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, H1 2019
  • Pruritus - Pipeline by RDD Pharma Ltd, H1 2019
  • Pruritus - Pipeline by Roivant Sciences Ltd, H1 2019

List of Figures

  • Number of Products under Development for Pruritus, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
目次
Product Code: GMDHC11181IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H1 2019, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pruritus - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 6, 13, 4, 1 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Pruritus - Overview
  • Pruritus - Therapeutics Development
  • Pruritus - Therapeutics Assessment
  • Pruritus - Companies Involved in Therapeutics Development
  • Pruritus - Drug Profiles
  • Pruritus - Dormant Projects
  • Pruritus - Discontinued Products
  • Pruritus - Product Development Milestones
  • Appendix
Back to Top